Abaloparatide

FDA-approved
Calculate Dose

For research use only.

Key Facts

CAS
247062-33-5
Molecular Weight (MW)
3961.6 g/mol
Half-life
~1–1.7 hours
Unit
mcg
Administration Route
Subcutaneous
Frequency
Once daily
Last updated
2/17/2026
Targets
PTH1 receptorOsteoblasts

Overview

—

Protocol

Dosage Range
80 mcg daily
Frequency
Once daily
Cycle
Maximum 2 years of treatment
Administration Route
Subcutaneous
Reconstitution Guide
Prefilled pen - no reconstitution needed

Science

Mechanism of Action

Agonist at PTH receptor type 1, activates cAMP signaling, stimulates bone formation, increases BMD, reduces fractures.

Targets

PTH1 receptorOsteoblasts

Studies

  • — Journal/year not available
  • — Journal/year not available

Benefits

Increased bone mineral densityReduced vertebral and nonvertebral fracturesAnabolic bone formationImproved bone microarchitecture

Potential Side Effects

  • Nausea
  • Leg cramps
  • Dizziness
  • Headache
  • Orthostatic hypotension
  • Hypercalcemia
  • Injection site reactions
  • Increased risk of osteosarcoma (long-term)

References

Related peptides

5-Amino-1MQ
Fat Loss
View details →
Acetyl Hexapeptide-8
—
View details →
Acetyl Octapeptide-3
—
View details →
Adamax
Cognitive
View details →
Afamelanotide
—
View details →
Angiotensin (1-7) Analog
—
View details →